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SUMMARY

For the past decade, cancer genomic studies have
focused on mutations leading to splice-site disruption, overlooking those having splice-creating potential. Here, we applied a bioinformatic tool, MiSplice,
for the large-scale discovery of splice-site-creating
mutations (SCMs) across 8,656 TCGA tumors. We
report 1,964 originally mis-annotated mutations
having clear evidence of creating alternative splice
junctions. TP53 and GATA3 have 26 and 18 SCMs,
respectively, and ATRX has 5 from lower-grade
gliomas. Mutations in 11 genes, including PARP1,
BRCA1, and BAP1, were experimentally validated
for splice-site-creating function. Notably, we found
that neoantigens induced by SCMs are likely several
folds more immunogenic compared to missense mutations, exemplified by the recurrent GATA3 SCM.
Further, high expression of PD-1 and PD-L1 was
observed in tumors with SCMs, suggesting candidates for immune blockade therapy. Our work highlights the importance of integrating DNA and RNA

data for understanding the functional and the clinical
implications of mutations in human diseases.
INTRODUCTION
Large-scale sequencing studies, such as The Cancer Genome
Atlas (TCGA) project, have worked to address the functional consequences of genomic mutations in tumors (Dees et al., 2012;
Kandoth et al., 2013; Lawrence et al., 2013; Niu et al., 2016),
with the larger goal of determining the underlying mechanisms
of cancer initiation and progression. Many studies have focused
on characterizing (1) non-synonymous somatic mutations that
alter amino acid sequence and (2) splice-disrupting mutations
at splice donors and acceptors (Jung et al., 2015). Current annotation methods typically classify mutations as disruptors of
splicing if they fall on either the consensus intronic dinucleotide
splice donor, GT, or the splice acceptor, AG. As a group, splice
site mutations have been presumed to be invariably deleterious
because of their disruption of the conserved sequences that are
used to identify exon-intron boundaries.
While this classification method has been useful, increasing
evidence suggests that splice site mutations can lead to transcriptional changes beyond disruption of the canonical junction
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(Lim and Fairbrother, 2012; Mort et al., 2014; Rivas et al., 2015;
Sauna and Kimchi-Sarfaty, 2011; Steffensen et al., 2014). One
such example is the c.190 mutation in BRCA1. Conventional
annotation had predicted a missense mutation, p.C64G, but
our analysis of RNA sequencing (RNA-seq) data in ovarian
tumors harboring p.C64G and a published mouse model (Yang
et al., 2003) suggested the germline c.190 mutation leads to
the creation of an alternative splice junction, resulting in a truncated null protein. Several case studies have reported observations of missense and silent mutations activating cryptic splice
sites in MLH1 (Nyström-Lahti et al., 1999), LMNA (Woolfe
et al., 2010), RB1 (Zhang et al., 2008), RNASEH2A (Rice et al.,
2013), MECP2 (Sheikh et al., 2013), BAP1 (Wadt et al., 2012),
and KIT (Chen et al., 2005), and other studies relate missense
and silent mutations to splicing changes (Jung et al., 2015;
Kahles et al., 2016; Soemedi et al., 2017; Supek et al., 2014).
Despite the broad clinical ramifications of mutation-induced
altered splicing, a systematic evaluation of their occurrence
and the resultant effects in cancer has yet to be undertaken,
and there have not been significant bioinformatics platforms
for doing so.
We developed a bioinformatic tool called MiSplice (mutationinduced splicing) that integrates DNA and RNA-seq data
across thousands of samples to discover mutations that induce
splice site creation. In our large-scale analysis across 8,656
tumor samples, we report 1,964 such somatic mutations that
had originally been mis-annotated. Splice-site-creating mutations (SCMs) are enriched in the new introns, with the highest
rate at the 3 nt position of acceptors with two-thirds of
such events at aGag and agGag repeats by creating an alternative junction 2 nt away. Partial and full splice creation capabilities across these 1,964 sites were evaluated by measuring the
fraction of reads supporting the alternative junction, which we
termed the ‘‘junction allele fraction’’ (JAF) and which is found
to be negatively correlated with distance to the new splice
site. In total, 1,607 genes harbor SCMs, with 248 of them
having more than one mutation, including TP53, GATA3,
ATRX, and NF1. Recurrent SCMs were found in TP53,
GATA3, DDX5, KDM6A, PTEN, SETD2, SMAD4, BCOR,
SPOP, and BAP1, suggesting an association with cancer
development. Broadly speaking, integrated DNA and RNA
data can furnish a sound basis for discovering SCMs and for
accurately understanding functional consequences of mutations in cancer and in other human diseases.
RESULTS
Splice-Site-Creating Mutation Discovery
We collected high-quality mutation calls from 8,656 tumors
across 33 cancer types derived from The Cancer Genome Atlas
having available TCGA RNA-seq data (STAR Methods). For
every mutation, we defined a set of control samples in the
same cancer cohort that lacked the same mutation in the gene
of interest. We sought to assess the landscape of SCMs across
cancer genomes by evaluating all mutations already having conventional annotations and their potential splice-site-creating
effects (Figure 1A). To achieve this goal, we conducted analysis
using a bioinformatic tool, MiSplice (mutation-induced splicing),

that systematically evaluates mutations in a splicing context
using RNA-seq data (Figure 1B).
MiSplice manages large analyses using parallel computation
to search for alternative splice junctions within windows of
±20 bp from the mutation of interest. For example, of the
1,416,566 candidate mutations examined here, 4,448 had five
or more unique RNA-seq reads supporting the predicted alternative junction in proximity to the mutation. MiSplice then conducts
a series of further evaluations, including Ensembl-based filtering
of canonical junctions, establishing observational significance
by case comparison to a matched set of controls, and assessing
score and depth of each cryptic site using MaxEntScan (Yeo and
Burge, 2004) and SamTools (Li et al., 2009). From the resultant
subset, MiSplice filters out human leukocyte antigen (HLA)
genes and sites whose junctions have insufficient difference
of expression, as judged from the case-control assessment.
Here, we evaluated promising alternative junctions with at least
5% of paired-end RNA-seq reads at the genomic location supporting the alternative junction of interest.
MiSplice processing revealed 2,056 mutations (Table S1) that
potentially create an alternative splice site. Manual review indicated a 2.09% false-positive rate, suggesting high specificity
of the MiSplice algorithm for discovering these types of mutation-induced splicing events. Of these putative splice events,
1.90% and 0.47% are considered complex and are in highly
homologous gene regions, respectively, so they were excluded
from further analyses (STAR Methods).
Of the final 1,964 SCMs passing manual review (Table S1),
52% (1,016) are in annotated splice sites, suggesting disruption
of the canonical splice site and selection of a the alternative
splice site nearby (Figure 1C). Importantly, 26% (513) and 11%
(208) of the SCMs had previously been mis-annotated as
missense and silent mutations, respectively. In addition, we
found 58 insertions or deletions, 46 nonsense, and 123 non-coding region mutations that likewise create cryptic splicing sites.
Molecular and Biological Patterns of SCMs
Next, we characterized the sequence context for the 1,790
SCMs corresponding to single nucleotide mutations. The
sequences of each 9-mer (donor) and 23-mer (acceptor)
covering the mutation position were extracted for both the
mutant and the reference sequences. Their splice scores as
potential donor or acceptor sites were then estimated using
MaxEntScan (Table S1).
Mutations near the alternative splice junctions show higher
mutation rates in the introns for both 50 (p < 1 3 105, binomial
test) and 30 splice site (p < 1 3 106) (Figure 2A). More interestingly, we found an enrichment of mutations at the third nucleotide position in the intron, but depletion at the first and second
positions (especially for 30 splice site) (Figure 2A). Comparison
of splicing scores between splice-site-creating mutants and
reference forms shows that most mutants have stronger splice
signals than the reference (Figure 2B). Mutations that create
a G or T to produce an alternative 50 splice site dramatically
increase splice site strength. For 30 splice sites, mutations enriched on the third nucleotide of the newly created intron showed
the largest increase of splicing score (Figure 2B). Further examination of the sequence context around mutations at the third
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Figure 1. Splice-Site-Creating Mutation Discovery
(A) Examples of splice-site-creating mutations for different conventionally annotated mutation types. Splice-in is defined as mutations contained within the newly
created exons, and splice-out is when the mutation is present in the newly created intron.
(B) The MiSplice workflow consists of three steps: alternative junction discovery, filtering, and manual review. First, the user inputs the locations of RNA-seq BAM
files along with a mutation file. MiSplice searches the BAM file to identify any alternative splice junctions near the mutation of interest, while filtering out known
splice junctions and calculating the number of alternative junction-supporting reads for case and control samples. For the filtering step, the following sites are
removed: mutations in HLA genes, a low fraction of reads supporting the alternative splice junction, and sites expressed in controls. Finally, we manually reviewed
all sites to validate the in silico predictions.
(C) Breakdown of 2,056 manually validated splice-site-creating mutations by conventional annotation.

nucleotide of 30 splice sites shows that 53% have a mutation on
aGag repeats and another 16% are mutated on agGag repeats,
all creating alternative junctions 2 nt away from the annotated
ones (Figure 2C). Mutations at the 3 position of the alternative
acceptor site would potentially enhance U2AF1 recognition of
the acceptor splice site. Previous studies have reported S34F
U2AF1 mutants preferentially skip exons that contain a T nucleotide at the 3 position (Okeyo-Owuor et al., 2015). Of the 192
mutations located at the 3 position from the alternative junction
and that contain an AG in the 2 and 1 positions, 56% undergo
a G > C transversion (21% G > A, 18% G > T, 3% C > T, 2% A > C,
1% A > T), with C being the preferred base at the 3 position for
U2AF1 binding (Figure 2D).
We also explored the relationship between the alternative and
canonical splice junctions. As expected, mutations at splice sites
dramatically reduced splice scores of the canonical splice junctions, while strengthening those at the alternative splice junctions in most cases. In contrast, a subset of missense and silent
mutations did not drastically alter the canonical junction, but
instead preferentially strengthened a nearby alternative splice
site (Figure 2E). When analyzing the raw splicing scores (canonical and alternative site before and after mutation), we found that
1,089 out of 1,790 (61%) events showed higher splice score for
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the alternative splice site than the canonical site, indicating inclination for the alternative sites. Further, while 485 (27%) events
saw lower post-mutation alternative splice score, differences
between alternative and canonical scores had decreased, suggesting that these mutations are still likely enhancing the preference for the alternative site. Only 214 (12%) events did not show
evidence, suggesting increased post-mutational preference for
using the alternative site. These cases are a good illustration of
the fact that many other genomic splicing features are also relevant, including exonic splicing enhancers (ESE), polypyrimidine
tract, branch point, and RNA-binding proteins. They are also
consistent with the general view that splice score is not definitive
(Jian et al., 2014). We emphasize that all 1,790 alternative splice
sites demonstrated usage based on patient RNA-seq data and
that 10 out of 11 (>90%) identified SCMs were validated experimentally (see below).
Expressivity and Penetrance of SCMs
In the presence of the mutation, alternative splice junctions
exhibited a wide range of expression. To quantify this effect,
we measured alternative junction expression as the fraction of
alternatively spliced junction spanning reads over the total number of reads at the genomic location, what we refer to as the JAF.
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D

E

Figure 2. Sequence Contexts and Characteristics of Splice-Site-Creating Mutations
(A) Frequency distribution of splice-site-creating mutations relative to the newly created splice junction, with high frequency shown at the third nucleotide position
in the newly created intron.
(B) Comparison of splicing scores for the newly created splice site, before (reference) and after the mutation (mutant). A larger effect of mutations at the third
nucleotide position in the intron (especially for the 30 splice sites) is shown.
(C) Dominant nucleotide sequence context for splice-site-creating mutations at 3 position of the 30 splice site. Mutation position (red dot) is present 3 base pairs
away from the newly created exon.
(D) Transition and transversion rate at the 3 position of the 30 splice site. Most mutations are G > C transversions, strengthening the consensus sequence of the
splicing factor U2AF1.
(E) Comparison of splicing scores between the nearest canonical splice junction with and without a mutation compared to the newly created splice junction with
and without a mutation. Most mutations strengthen the alternative splice junction relative to the canonical splice junction.

Figure 3A shows the distribution of JAF’s for all high confidence
MiSplice predicted alternative junctions, separated by conventional mutation annotations (Figure 3A). Currently, we use a
JAF cutoff of 5% for reporting the final high-confidence sites.
However, there are some potential alternative sites excluded
by this cutoff. Our analysis revealed alternative junction expres-

sion varies widely. As expected, DNA variant allele fraction (VAF)
and JAF have a generally positive correlation (Figure 3B), with
SCMs in KDM6A and FGFR2 having >75% DNA VAF and JAF.
However, a SCM in ARID1A has a DNA VAF of 23% and JAF
of 67%. Such large ranges have been noted for mutations
outside of the splice site (Broeks et al., 2003; Clarke et al.,
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Figure 3. Junction Allele Fraction of Splice-Site-Creating Mutations
(A) The junction allele fraction (JAF) is defined as the number of reads supporting the alternative spliced junction relative to total junction spanning reads. Distribution of JAF values separated by conventional annotation type.
(B) JAF versus DNA variant allele fraction (VAF) comparison by conventional annotation type. Most mutation types show a generally positive correlation between
JAF and VAF values.
(C) Splice-site-creating mutations expressed in the newly created exon of the alternative splice junction. Comparison of mutation position relative to the percent
of reads supporting the alternative junction and mutation (spliced-in JAF). The mean of each position is highlighted by the black point. For all positions, there is a
strong correlation between the presence of the splice-site-creating mutation and the alternative splice junction.

2000; Venables, 2004). Both the truncated and normal spliced
products can be observed for many variants, due to either the
wild-type allele or leaky splicing, for example, as observed in
RNASEH2A, NFU1, SMN1, CFTR, and NF2 (Boerkoel et al.,
1995; Caminsky et al., 2014; Ferrer-Cortès et al., 2016; Lohmann
and Gallie, 2004; Mautner et al., 1996; Pagani et al., 2003; Rice
et al., 2013; Svenson et al., 2001; Vezain et al., 2011).
Next, we considered the expression of mutations that are
spliced-in, i.e., mutations located within the exon of the alterna-
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tively spliced product. To this end, we determined the ratio of the
number of alternative junction reads containing the mutation
versus total number of reads supporting the alternative junction
(Figure 3C; Table S1). Overall, most of the reads supporting the
alternative junction also support the mutation, a finding that suggests a strong association between the mutation and alternative
splice junction. Regarding the 50 splice site, mutations within the
first 6 bp of the new exon junction have a much higher fraction
of alternative junction reads supporting them; and we see an
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Figure 4. Splice-Site-Creating Mutations across Genes and Cancer Types
(A) Distribution of splice-site-creating mutations in each gene separated by the total number of mutations in each gene. TP53 has the largest number of splicesite-creating mutations, followed by GATA3 and ATRX.
(B) Genes with the highest number of pancancer splice-site-creating mutations. Circle size correlates with the total number of mutations for each gene (labeled
inside circle) and colored by cancer type. Splice-site-creating mutations in TP53 are present in many cancer types, while mutations in ATRX and GATA3 are
specific to LGG and BRCA, respectively.
(C) Proteins Timeless (PAB domain) and PARP1 (chain A) are colored green and pink, respectively. Originally annotated p.S939S mutation (red) and spliced-out
sequence (blue) are highlighted on PARP1 (chain A).
(D) 3D protein structure of PARP1 in complex with an inhibitor (PDB ID: 5WRQ). Drug inhibitor and PARP1 (chain A) are indicated in green and pink, respectively.

inverse correlation between the mutation and the junction as the
distance between them increases. For the 30 splice site, we
observe a similar trend, although with a higher variability as a
function of the distance from the alternative junction.
SCMs across Genes and Cancer Types
A total of 1,607 unique genes harbored SCMs, with 85% (1,359)
having one mutation and 15% (248) having two or more. TP53
contained the greatest number (26), followed by GATA3 (18).
While most SCMs were found outside the current cancer gene
compendium (Table S1), Figure 4A shows that a remarkable
number of cancer genes harbor splice altering variants, a phenomenon supported in the literature (Sebestyén et al., 2016).
A pan-cancer view reveals that TP53 was the most mutated
across cancer types, while 18 GATA3 mutations and 6 ATRX mutations were specific to breast cancer (BRCA) and lower-grade
glioma (LGG), respectively.
We observed 137 mutations nearby to one another (±5 bp)
which lead to the creation of the same recurrent splice-sitecreating events, not only in TP53 but also in GATA3, DDX5,
KDM6A, SETD2, PTEN, SPOP, and BAP1. While some mutations
did not occur at the same position, 14 mutations creating the same
alternative splice junction were found in the same exon, including
2 mutations in the third exon of BAK1. While most mutations in
close proximity created the same alternative splice junction, two
adjacent SCMs in CTNND1 and 2 nearby exonic mutations in
ACP2 and GMPPB created different alternative junctions.

SCMs can impact protein structure and have potential therapeutic implications. Poly ADP-ribose polymerase 1 (PARP1) is
an enzyme involved in recruiting protein members of DNA repair
pathways including Timeless PAB (PARP1 binding domain) (Figure 4C) (Xie et al., 2015). Since PARP1 is essential to many
cellular processes, including DNA repair, it is commonly targeted by antitumor agents (Malyuchenko et al., 2015). PARP1
inhibitors targeting the catalytic domain disrupt DNA repair
mechanisms thereby increasing the effectiveness of chemotherapeutic agents (Figure 4D). Identifying mutations that
disrupt inhibitor binding are essential to properly evaluate treatment options. MiSplice identified a conventionally annotated
silent PARP1 mutation (p.S939S) in a lung squamous cell carcinoma (LUSC) patient that acts as a splice-site-creating variant
by creating a de novo donor site (Figure 5A). 82 reads supported the de novo donor site, which results in a 10 amino
acid deletion (p.940-p.950) that falls within the catalytic domain
(Figure 4D). Out of 173 LUSC control samples, none contained
reads supporting the alternative junction, providing strong evidence that the annotated ‘‘silent’’ mutation is actually a SCM.
Previous reports of missense mutations at p.940 are predicted
to reduce PARP1 enzymatic activity by disrupting the binding
affinity of PARP1 to its substrate NAD+ (Alshammari et al.,
2014). The in-frame SCM likely disturbs the local structure of
PARP1 and thereby disrupts the interactions between PARP1,
its protein binding partners, and drugs binding within the pocket
(Figures 4C and 4D).
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Figure 5. Minigene Functional Assay of Splice-Site-Creating Mutations
(A) Integrative genomics viewer (IGV) screenshot of the conventionally annotated synonymous mutation in PARP1 in exon 21. RNA-seq reads of the candidate
splice-site-creating mutation reveal the creation of an alternative splice site (red reads) created by the conventionally annotated synonymous mutation.
(B) Candidate recurrent splice-site-creating mutations in BAP1. Conventionally annotated as synonymous variants, the BAP1-mutated region shows alternatively
spliced reads (red reads) in the IGV screenshot for each sample with the splice-site-creating mutation.
(C) IGV screenshot of a conventionally annotated synonymous mutation in RAD51C in exon 2.
(D) Maximum entropy score of the splice-site-creating variant before (purple) and after (red) the introduced mutation for each variant functionally validated in the
mini-gene splicing assay. In silico predictions suggest all mutations strengthen the alternative splice site.
(E) Candidate splice-site-creating mutations validated by the mini-gene splicing assay. Exons of interest were cloned into the pCAS2.1 vector and mutant (red);
wild-type (purple) plasmids were transfected into 293T cells; and total RNA was extracted to identify mutation-induced alternatively spliced products.

We identified two kidney renal clear cell carcinoma (KIRC) samples having the same conventionally annotated missense mutation (c.233A > G, p.N78S) in BAP1, a nuclear deubiquitinase,
that created the same spliced-out alternative splicing product
(Figure 5B). Inactivation of BAP1 is prevalent among renal cell
carcinomas (Peña-Llopis et al., 2012) and an annotated missense
mutation (p.L570V) has been reported to create a cryptic splice
site in melanoma (Wadt et al., 2012). At the transcriptional level,
the expressions of the case and control samples are relatively
comparable, but at the translational level, one case with available
protein data (RPPA) showed significantly lower expression
(p = 0.044, permutation test) relative to the controls (Figure S1;
Table S2). This result suggests the conventionally annotated
missense mutations in BAP1 likely create an alternatively spliced
transcript that is not readily expressed at the protein level.
We used a pCAS2.1 splicing reporter mini-gene functional
assay that was adapted from previous publications (Bonnet
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et al., 2008; Gaildrat et al., 2010; Malone et al., 2016; Tournier
et al., 2008; Vreeswijk and van der Klift, 2012), to validate
SCMs in 11 cancer genes, including two originally annotated
silent mutations in PARP1, RAD51C, two splice site mutations
in TP53 and BRCA1, and several missense mutations in
ARID2, BAP1, BCOR, CDH1, KMT2A, PTEN, and TSC2. Wildtype and mutant exons were cloned into a pCAS2.1 vector (Gaildrat et al., 2010) and transiently transfected into HEK293T cells.
Total RNA was extracted to evaluate alternatively spliced products by RT-PCR. Examining the change in the MaxEntScan
score for the 11 genes revealed mutations in ARID2, BAP1,
BCOR, CDH1, PARP1, RAD51C, PTEN, and TSC2 having
dramatically stronger splice scores in the presence of the mutation, while mutations in BRCA1, KMT2A, and TP53 did not (Figure 5D). Except for PTEN, variants with stronger splice scores
showed higher levels of the alternatively spliced product in the
mini-gene assay when compared to the wild-type. Variants

with moderate changes in splice score still showed evidence of
alternatively spliced transcripts, revealing the importance of utilizing functional assays to evaluate the effect of mutations in a
splicing context in addition to in silico predictions. The minigene assay confirmed 91% (10/11 genes) splicing alterations
in all tested genes and sequencing confirmed the alternatively
spliced products (Figure 5E; STAR Methods), suggesting a
strong concordance between MiSplice predicted SCMs and
the functional assay.
Neoantigens Introduced by SCMs
We have further investigated neoantigens produced by SCMs. By
using the RefSeq transcript database, a total of 2,993 protein
sequences were translated for transcripts containing mutationinduced alternative splice forms (Table S3). In the translation,
we allowed for different transcripts from each SCM. The HLA
types for each sample were adopted from the TCGA pancan
immune working group (Synapse ID: syn5974636). NetMHC4
and NetMHCpan-3.0 (Andreatta and Nielsen, 2016) were used
to predict the binding affinity between epitopes and the major histocompatibility complex (MHC) and showed a high concordance
in total predicted neoantigens (Pearson = 0.94; Figure S2). We
found that alternative splice forms for some important genes
related to tumorigenesis, including SMARC1, KDM6A, and
NOTCH1, are highly immunogenic and can contain 40 or more
unique neoantigens (Figure 6A) (Dalgliesh et al., 2010; Papadakis
et al., 2015). In addition, the mean number of neoantigens across
SCMs from NetMHCpan-4.0 and NetMHCpan-3.0 are 2.0 and
2.5, respectively, which are both higher than the average number
of around 1 for non-synonymous mutations. Furthermore, 28
genes contain recurrent neoantigen events (R3) across samples
(Figure 6B). In particular, GATA3 has the highest recurrence and
GATA3 SCMs were mutually exclusive with other mutation types
(Figure 6C). The CA deletion at chr8:8111433 disrupts the canonical splice site and an alternative splice site is used for creating the
alternative splice form, which results in a frame shifted protein
product spanning the Zinc-finger domain (Figures 6D and 6E).
19 unique neoantigen peptide sequences were mapped to the
frameshifted protein product for the 16 samples (Figure 6F). We
were further able to validate one alternative peptide sequence
using mass spectrometry data from a recent proteogenomics
study on 77 TCGA breast cancer patients (Mertins et al., 2016).
For one sample with the highly recurrent and expressed GATA3
SCM, we used MSGF+ to search publicly available mass spectrometry data for evidence of alternative GATA3 peptides. Figure 6G shows one identified mass spectrum supporting one alternative GATA3 peptide, which covers two immunogenic peptides
(KPKRRLPG and LIKPKRRLPG) predicted in TCGA-AR-A1AP.
High neoantigen burden is associated with an elevated
immune response (Turajlic et al., 2017). To test whether SCMs
affect immune response, we compared the expression of T cell
markers PD-1, CD8A and CD8B and PD1 immune checkpoint
blockades PD-L1 and PD-L2 (Figure 7). We selected six cancer
types (BRCA, BLCA, HNSC, LUAD, LUSC, and SKCM) with sufficient samples containing SCMs for adequate statistical power.
Both T cell markers (PD-1, CD8A, and CD8B) and immune
checkpoint blockade PD-L1 show increased expression in samples with SCMs compared to samples without SCMs (Figure 7),

indicating alternative splice forms induced by SCMs increase the
overall immunogenicity of these cancers. The highly expressed
PD-L1 suggests PD-L1 immunotherapy as potential treatments
for samples containing SCMs.
DISCUSSION
In this study, we applied our newly developed bioinformatics tool
called MiSplice (mutation-induced splicing) to systematically
analyze splice-site-creating events that arise from somatic mutations. Our analysis shows MiSplice reliably identifies SCMs
across multiple cancer types. Existing studies have largely
focused on splice-disrupting events in known splice sites, but
the current study substantially extends our knowledge into the
realm of SCMs in human cancer. For instance, we found 1,016
splice site mutations not only disrupt the canonical splice site
but also create an alternative splice site. We also found that
hundreds of mutations that would traditionally be classified as
missense, silent, indel, and nonsense are really acting as
SCMs. Many important cancer-related genes harbor these mutations, such as TP53, ATRX, BAP1, CTNNB1, RB1, etc. It is
noteworthy that we found five SCMs in ATRX among 288 LGG
cases, likely leading to the disruption of ATRX function. A previous study has shown that loss of wild-type ATRX is associated
with tumor growth in glioma (Koschmann et al., 2016).
Characterization of these alternative splice events show that
most SCMs have a higher splice score, as measured by
MaxEntScan, in the post-mutation alternative splice site as
compared to the reference. These results are consistent with
the preferential selection of these alternative sites as new splicing
forms. For the splice-site mutation, the splice score associated
with the canonical junction is coincidently decreased after mutation. However, while there is no difference in splice scores of
canonical junctions before and after missense and silent mutations, the alternative splice site was often strengthened after
mutation. This suggests silent and missense mutations instead
act as modifiers of splicing by creating or strengthening cryptic
sites within the exon as opposed to disrupting the canonical splice
site. In addition, we found a significant enrichment of mutations at
the 3 position in the 30 splice site, the two dominant sequence
contexts being aGag and agGag, where G is at the 3 position.
In cases in which the mutation is retained in the alternative
splice junction, we distinguish mutations with two further categories, splice-in and splice-out. For splice-in mutations, we
can characterize the association between mutations and cryptic
splicing forms. For example, we found high concordance for
RNA-seq reads supporting alternatively spliced junctions and
mutations, suggesting the association between mutations and
cryptic splicing forms.
The current study has greatly extended insights into the transcriptional ramifications of genomic alterations by identifying
nearly 1,964 alternative splice sites introduced by somatic mutations and functionally validating 10 of 11 variants in a mini-gene
splicing assay. These events were conventionally annotated
as missense, silent, splice site, nonsense, or other mutations
when, in fact, we have shown that they often create cryptic splice
sites. This relative abundance of the alternative and wild-type
product suggests varying levels of junction usage, depending
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Figure 6. Schematic of GATA3 Splice-Site-Creating Mutations and Neoantigen Predictions
(A) Distribution of neoantigens predicted by NetMHCpan and NetMHC4. Genes with the highest number of neoantigens labeled. Mean value for each tool
indicated by X and labeled.
(B) Genes with the largest recurrence of predicted neoantigens across the dataset. GATA3 shows the highest recurrence.
(C) Mutual exclusivity of protein-affecting mutation (PAM), frameshifting indel (FS), in-frame indel (IF), and splice-site-creating mutations (SCM) in GATA3. (D) IGV
screenshot of GATA3 splice-site-creating mutation, which disrupts the canonical splice site and utilizes a cryptic splice site 7 bp downstream. Mutant reads
highlighted in red, and normal reads are in purple. CA deletion indicated in the figure.
(E) Predicted functional domains disrupted because of the recurrent splice-site-creating mutation in GATA3.
(F) Predicted neoantigen peptide sequences mapped to the frameshifted protein product for samples with GATA3 SCMs.
(G) Mass spectrum of GATA3 peptide in TCGA-AR-A1AP.
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Figure 7. PD-L1, PD-L2, PD-1, CD8A, and CD8B Expression
(A) Expression comparison of PD-L1, PD-L2, and T cell markers PD-1, CD8A, and CD8B between samples with (case) and without (control) SCMs across six
cancer types. p values: * less than 0.05; ** < 0.01; and *** < 0.001; ns, not significant.

on the context of the mutation, and emphasizes the importance
of validating predictions using a functional assay to understand
the full biological consequence. The alternative products may
be therapeutically targetable in some cancer patients. For
example, targeting neoantigens shows promising results in treating melanoma patients (Carreno et al., 2015). By further evaluating human leukocyte antigen (HLA) genotypes and binding
affinities to the MHC, it is likely that new neoantigens from cryptic
splice sites may be discovered. The current study reveals that
alternative splice forms induced by SCMs are highly immunogenic and correlated with a high T cell immune response and
an elevated PD-L1 expression, suggesting the potential for
immunotherapy in these samples. Further investigation of the
cryptic splice sites by mass spectra or target assay are needed
to prioritize therapeutic targets in clinical trials.
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Robinson et al., 2011
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Nucleospin PCR Cleanup

Macherey-Nagel

740609.10

DNA Clean and Concentrator-5 Kit

Zymo Research

D4003

BamHI

New England Biomedicine

R0136S

MluI

New England Biomedicine

R0198S

T4 DNA Ligase

New England Biomedicine

M0202S

Q5 Site Directed Mutagenesis

New England Biomedicine

E0554S

Lipofectamine 2000

Thermofisher Scientific

12566014

Superscript III First-Strand Synthesis System

Thermofisher Scientific
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Qiaquick Gel Extraction Kit
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28704

Public MC3 MAF
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Li Ding
(lding@wustl.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
The Cancer Genome Atlas (TCGA) collected both tumor and non-tumor biospecimens from 10,224 human samples (https://
cancergenome.nih.gov/abouttcga/policies/informedconsent). Here, we use variants from a publicly available mutation annotation
file (MAF) complied by the MC3 working group (syn7824274).
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METHOD DETAILS
Dataset Description
Aligned RNA-seq bam files were analyzed using the ISB google. These cancer types are Acute Myeloid Leukemia [LAML], Adrenocortical carcinoma [ACC], Bladder Urothelial Carcinoma [BLCA], Brain Lower Grade Glioma [LGG], Breast invasive carcinoma
[BRCA], Cervical squamous cell carcinoma and endocervical adenocarcinoma [CESC], Cholangiocarcinoma [CHOL], Colon adenocarcinoma [COAD], Esophageal carcinoma [ESCA], Glioblastoma multiforme [GBM], Head and Neck squamous cell carcinoma
[HNSC], Kidney Chromophobe [KICH], Kidney renal clear cell carcinoma [KIRC], Kidney renal papillary cell carcinoma [KIRP], Liver
hepatocellular carcinoma [LIHC], Lung adenocarcinoma [LUAD], Lung squamous cell carcinoma [LUSC], Lymphoid Neoplasm
Diffuse Large B cell Lymphoma [DLBC], Mesothelioma [MESO], Ovarian serous cystadenocarcinoma [OV], Pancreatic adenocarcinoma [PAAD], Pheochromocytoma and Paraganglioma [PCPG], Prostate adenocarcinoma [PRAD], Rectum adenocarcinoma
[READ], Sarcoma [SARC], Skin Cutaneous Melanoma [SKCM], Stomach adenocarcinoma [STAD], Testicular Germ Cell Tumors
[TGCT], Thymoma [THYM], Thyroid carcinoma [THCA], Uterine Carcinosarcoma [UCS], Uterine Corpus Endometrial Carcinoma
[UCEC], Uveal Melanoma [UVM]
MiSplice Pipeline
The MiSplice pipeline was developed to detect mutation-induced splicing events from RNA-seq data. It is written in Perl and
incorporates two standard tools, samtools and MaxEntScan. The pipeline is fully automated and can run multiple jobs in parallel
on LSF cluster. It executes the following steps:
1) Splitting large maf file into multiple smaller files with less mutations (currently, the default setting is 200).
2) Discovering splicing junctions within 20bps of the mutation with at least 5 supporting reads with mapping quality Q20 and then
filtering canonical junctions by using the Ensembl 37.75 database. We selected 20bp as a cut-off since it is the farthest
distance from the splice junction in a splice region.
3) Computing the number of supporting reads of above cryptic splice sites for control samples without mutations (Table S1).
4) Calculating the splicing scores for the cryptic splice sites via MaxEntScan.
5) Reporting the depth of each cryptic splice site via Samtools.
6) Filtering cryptic sites which fall in HLA loci or less than 5% of reads at the genomic location supporting the alternative junction
of interest.
7) Further filtering cryptic sites by comparing the supporting reads in control samples. The final reported cryptic sites must stand
as top 5% for the number of supporting reads in the case (with mutation).
Splice Site Score Estimation
For each cryptic splice site and nearby canonical splice site, the corresponding nucleotide sequences were first extracted for both
the mutant and reference sequences (9-mer and 23-mer for donor and acceptor, respectively). Their splice scores as potential donor
or acceptor sites were then estimated using MaxEntScan.
Neoantigen Prediction
For each predicted SCM, we use a curated RefSeq transcript database (version 20130722) to obtain the translated protein
sequences for transcript containing alternative splice forms induced by SCMs. Different length of epitopes (8-mer, 9-mer, 10-mer
and 11-mer) are constructed from the translated protein sequence. We use NetMHC3pan (Nielsen and Andreatta, 2016) and
NetMHC4 (Andreatta and Nielsen, 2016) to predict the binding affinity between epitopes and MHC. Epitopes with binding
affinity % 500nM which are also not present in the wild-type transcript are extracted from the following neoantigen analysis.
Manual Review
All splice-site-creating mutations were manually reviewed using the integrative genomics viewer (http://software.broadinstitute.org/
software/igv/). Mutations were placed into one of three categories: Pass, Complex, and No Support. Mutations were classified as
complex if more than one alternatively spliced product was observed for the mutated sample.
Code Availability
MiSplice is written in Perl and is freely available from GitHub at https://github.com/ding-lab/misplice under the GNU general public
license. MiSplice uses several independent tools and packages, including SamTools and MaxEntScan, all of which are likewise freely
available, but which must be obtained from their respective developers. The MiSplice documentation contains complete instructions
for obtaining and linking these applications into MiSplice.
Mini-gene Splicing Assay
Exons of interest and approximately 150 bp of their flanking intron sequences were PCR amplified from HEK293T genomic DNA using
primers carrying restriction enzyme sites for BamH1 and MluI. PCR products were cleaned up using NucleoSpin PCR Cleanup
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(Macherey-Nagel) or DNA Clean and Concentrator-5 Kit (Zymo Research) and digested with BamHI and MluI. The digested pCAS2.1
vector and PCR products were ligated using T4 DNA Ligase (NEB). Mutations were introduced via Q5 Site-Directed Mutagenesis
(NEB). WT and MUT constructs were confirmed by sequencing of the insert region. The plasmids were transiently transfected into
HEK293T cells using Lipofectamine 2000 (ThermoFisher Scientific). 24 hr post transfection, cDNA was synthesized using 2 to 3
ug of total RNA with the Superscript III First-Strand Synthesis System (ThermoFisher Scientific) and priming with Oligo(dT)20. Finally,
cDNA was amplified using pCAS-KO1-(50 -TGACGTCGCCGCCCATCAC-30 ) and pCAS-R (50 -ATTGGTTGTTGAGTTGGTTGTC-30 )
and the alternative splicing patterns were evaluated on a 2.5% agarose gel with ethidium bromide. Qiaquick Gel Extraction Kit
(QIAGEN) was used to purify bands for sequencing (Figures S3, S4, S5, and S6; Tables S5, S6, and S7).
Cell Culture
HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with fetal bovine serum (FBS) and penicillin streptomycin.
QUANTIFICATION AND STATISTICAL ANALYSES
MiSplice assesses the significance of the number of reads supporting the predicted alternative splice junction by comparing to read
counts from a control cohort. Specifically, a frequency distribution is constructed from the control cohort, from which threshold
values for 5% and 95% tails on the left and right, respectively, are determined. A series of logic tests is then conducted to discern
the best explanation of the data. Possible verdicts are low or high expression if the datum is outside the 5% or 95% thresholds,
respectively, average expression if no thresholds are exceeded, or no expression in this tissue if the thresholds are zero.

e3 Cell Reports 23, 270–281.e1–e3, April 3, 2018

Cell Reports, Volume 23

Supplemental Information

Systematic Analysis of SpliceSite-Creating Mutations in Cancer
Reyka G. Jayasinghe, Song Cao, Qingsong Gao, Michael C. Wendl, Nam Sy Vo, Sheila M.
Reynolds, Yanyan Zhao, Héctor Climente-González, Shengjie Chai, Fang Wang, Rajees
Varghese, Mo Huang, Wen-Wei Liang, Matthew A. Wyczalkowski, Sohini Sengupta, Zhi
Li, Samuel H. Payne, David Fenyö, Jeffrey H. Miner, Matthew J. Walter, The Cancer Genome Atlas Research Network, Benjamin Vincent, Eduardo Eyras, Ken Chen, Ilya
Shmulevich, Feng Chen, and Li Ding

Gene

Sample

Position

Reference

Mutation

Coding
Change

Amino Acid
Change

Transcript

ARID2

TCGA-FS-A1Z3

12: 46243434

T

A

c.1787T>A

p.Val596Glu

ENST00000334344

TSC2

TCGA-EE-A17Y

16:2098705

C

A

c.89C>A

p.Ser30Tyr

ENST00000219476

CDH1

TCGA-GC-A3I6

16:68863653

C

G

c.2392C>G

p.Leu798Val

ENST00000219476

TP53

TCGA-FG-A60J

17:7577157

T

G

c.783-2A>C

p.X261_splice

ENST00000269305

RAD51C

TCGA-32-1982

17:56772380

A

G

c.234A>G

p.Thr78Thr

ENST00000337432

BCOR

TCGA-DM-A1HA

X:39922049

A

G

c.4123C>T

p.Arg1375Trp

ENST00000378444.4

BAP1

TCGA-B0-5107 and
TCGA-CJ-4637

3: 52442512

T

C

c.233A>G

p.Asn78Ser

ENST00000460680

PARP1

TCGA-66-2791

1:226550831

G

A

c.2817C>T

p.Ser939Ser

ENST00000366794

BRCA1

TCGA-D6-6823

17:41256883

A

C

c.301+2T>G

p.X101_splice

ENST00000471181

PTEN

TCGA-06-2559

10:89692993

G

T

c.477G>T

p.Arg159Ser

ENST00000371953

KMT2A

TCGA-55-7994

11:118366474

G

T

c.5423G>T

p.Trp1808Leu

ENST00000534358

Supplemental Table 5: Mutation information for splice site-creating mutations validated in minigene
assay. Related to Experimental Procedures.

Gene

Primer Type

Forward Primer

Reverse Primer

ARID2

Genomic Primer

ATAAGGATCCTGGAATTGTTTAAAACCCAGCGA

AGCTACGCGTGACTGAAAATCCCAAGTAGGAA

ARID2

Q5 Mutagenesis

CATATTCATGaGGTAGGAGTAAAACGGAG

TGCCTGCCCATTGCTACT

TSC2

Genomic Primer

ATTTGGATCCTGTCTCCCGGGCTTTCCTA

ATATACGCGTCAGGTCACCAAGATCCTGACT

TSC2

Q5 Mutagenesis

AATCCCAGGTaTGCAGAGGGTAAAC

TGGCCTCGGTGTTCCCAG

CDH1

Genomic Primer

ATTTGGATCCCCAGTGCTATTTGGGAGACTT

ATATACGCGTGCTCAGGCAAGCTGAAAACAT

CDH1

Q5 Mutagenesis

CCCCCGGTATgTTCCCCGCCC

ACACTCATGAGGGTTGGTGCAACG

TP53

Genomic Primer

ATTAGGATCCGGACCTCTTAACCTGTGGCT

ATATACGCGTAGGAAAGAGGCAAGGAAAGGTG

TP53

Q5 Mutagenesis

TATCCTGAGTcGTGGTAATCTAC

GGAAAAGAGAAGCAAGAG

RAD51C

Genomic Primer

ATTAGGATCCTGCATTTTTATGTTTCTCCACTCCT

ATATACGCGTTGGTTTCCTGACGATAGTACAAAAT

RAD51C

Q5 Mutagenesis

ATGCTGGTACgTCTGAGTCAC

ATCTTGGTTTATTTGTGAGAC

BCOR

Genomic Primer

ATTTGGATCCTATCTTTAAAAACTGAAGCCGCTC

ATATACGCGTCTCCTCTAGGACAGGGGAGTG

BCOR

Q5 Mutagenesis

GGAGTCCAGGtGGGGATTGCC

TGAGGGATCAAGTGTTTGGTTTTGC

BAP1

Genomic Primer

TTACGGATCCGAGGCTTATGCTTTGCTCTGC

ATTGACGCGTAGAGAGTGGACTCAGACACCC

BAP1 (N78S)

Q5 Mutagenesis

GATATTGTGAgTAACATGTTCTTTGC

ATCATCAATCACGGACGTATC

BAP1 (I76T) Control

Q5 Mutagenesis

GATGATGATAcTGTGAATAACATG

AATCACGGACGTATCATC

BAP1 (V62V) Control

Q5 Mutagenesis

CCGGCGAAAGGTTTCTACC

GACCGGCGCTCTTCGA

PARP1

Genomic Primer

AATTGGATCCGCTCCTACATGGGGCAACAG

GCGTACGCGTCAGAGTTACGCTACCTCATCAT

PARP1

Q5 Mutagenesis

CACATATCAGtAAGTTACCCAAG

AAGCGTGCTTCAGTTCATAC

BRCA1

Genomic Primer

ATTAGGATCCGGTTTTCTACTGTTGCTGCATCTT

ATATACGCGTGGTCTTATCACCACGTCATAGAA

BRCA1

Q5 Mutagenesis

GTTTGGAGTGgAAGTGTTGAATATC

CTGTGTCAAGCTGAAAAG

PTEN

Genomic Primer

ATTAGGATCCGCATTGAGAGTCCTGACGAA

TGTAACGCGTAAACCTGTTTTCCAGGGACTGA

PTEN

Q5 Mutagenesis

GGGAAGTAAGtACCAGAGACAAAAAG

CATAGAAATCTAGGGCCTC

KMT2A

Genomic Primer

ATTAGGATCCGCATTGAGAGTCCTGACGAA

TGTAACGCGTAAACCTGTTTTCCAGGGACTGA

KMT2A

Q5 Mutagenesis

TATGCTCAGTtGCAGGAGCGA

ATTATGGTCAAGTGAAGGTG

Supplemental Table 6: Primer information for genes validated in minigene assay. Related to Experimental Procedures.

Type

RT-PCR Sequence

pCAS2.1

TGACGTCGCCGCCCATCACGCCTCCAGGCTGACCCTGCTGACCCTCCTGCTGCTGCTGCTGGCTGGGGATA
GAGCCTCCTCAAATCCAAATGCTACCAGCTCCAGCAGCCAAGATCCAGAGAGTTTGCAAGACAGAGGCGAAG
GGAAGGTCGCAACAACAGTTATCTCCAAGATGCTATTCGTTGAACCCATCCTGGAGGTTTCCAGCTTGCCGAC
AACCAACTCAACAACCAAT

BAP1 Wild Type

CCCTGTATATGGATTTATCTTCCTGTTCAAATGGATCGAAGAGCGCCGGTCCCGGCGAAAGGTCTCTACCTTGG
TGGATGATACGTCCGTGATTGATGATGATATTGTGAATAACATGTTCTTTGCCCACCAG

BAP1 Mutant

CCCTGTATATGGATTTATCTTCCTGTTCAAATGGATCGAAGAGCGCCGGTCCCGGCGAAAGGTCTCTACCTTGG
TGGATGATACGTCCGTGATTGATGATGATATT

TP53 Wild Type

CTCGCTTAGTGCTCCCTGGGGGCAGCTCGTGGTGAGGCTCCCCTTTCTTGCGGAGATTCTCTTCCTCTGTGC
GCCGGTCTCTCCCAGGACAGGCACAAACACGCACCTCAAAGCTGTTCCGTCCCAGTAGATTACCA

TP53 Mutant

CTCGCTTAGTGCTCCCTGGGGGCAGCTCGTGGTGAGGCTCCCCTTTCTTGCGGAGATTCTCTTCCTCTGTGC
GCCGGTCTCTCCCAGGACAGGCACAAACACGCACCTCAAAGCTGTTCCGTCCCAGTAGATTACCACGA

BCOR Wild Type

CTTGCCATCGGCATTCTCCACGTAGTATTCCCCTGTCAGTGGCAATCCCCGCCTGGACTCCTGAGGGATCAAG
TGTTTGGTTTTGCACAGTCTCTTCCCGGATGGCTTCTCGCTGTTGTCGGTGTATTTCTGCAGCAGGGAGGCAG
CCTGGCAATCCTCTTCTTCGTCTGCACACAGCACATCTGTCTTCTGGTTTTCTTTAATTTTCTGCTGTTTGGCAG
GCGGCCTGGAGGCTGGTGCGCAGCTTGGCTGAGCCTGCTTTTTGCCGCCTGCACTGGTGGATGAAAGACTC
TTCATGGGCGGAGAGCCGGAGAACACAGGCAAGC

BCOR Mutant

CTGGACTCCTGAGGGATCAAGTGTTTGGTTTTGCACAGTCTCTTCCCGGATGGCTTCTCGCTGTTGTCGGTGT
ATTTCTGCAGCAGGGAGGCAGCCTGGCAATCCTCTTCTTCGTCTGCACACAGCACATCTGTCTTCTGGTTTTCT
TTAATTTTCTGCTGTTTGGCAGGCGGCCTGGAGGCTGGTGCGCAGCTTGGCTGAGCCTGCTTTTTGCCGCCT
GCACTGGTGGATGAAAGACTCTTCATGGGCGGAGAGCCGGAGAACACAGGCAAGC

RAD51C Wild Type

AAGTTGGGATATCTAAAGCAGAAGCCTTAGAAACTCTGCAAATTATCAGAAGAGAATGTCTCACAAATAAACCAA
GATATGCTGGTACATCTGAGTCACACAAGAAGTGTACAGCACTGGAACTTCTTGAGCAGGAGCATACCCAGGG
CTTCATAATCACCTTCTGTTCAGCACTAGATGATATTCTTGGGGGTGGAGTGCCCTTAATGAAAACAACAGAAAT
TTGTGGTGCACCAGGTGTTGGAAAAACACAATTATG

RAD51C Mutant

AAGTTGGGATATCTAAAGCAGAAGCCTTAGAAACTCTGCAAATTATCAGAAGAGAATGTCTCACAAATAAACCAA
GATATGCTG

KMT2A Wild Type

CAGTGGGATGTTACCAAACGCAGTGCTTCCACCTTCACTTGACCATAATTATGCTCAGTGGCAGGAGCGAGAG
GAAAACAGCCACACTGAGCAGCCTCCTTTAATGAAGAAAATCATTCCAGCTCCCAAACCCAAAGGTCCTGGAG
AACCAGACTCACCAACTCCTCTGCATCCTCCTACACCACCAATTTTGA

KMT2A Mutant

TTGCAGGAGCGAGAGGAAAACAGCCACACTGAGCAGCCTCCTTTAATGAAGAAAATCATTCCAGCTCCCAAAC
CCAAAGGTCCTGGAGAACCAGACTCACCAACTCCTCTGCATCCTCCTACACCACCAATTTTGA

PARP1 Wild Type

CTTTGACACTGTGCTTGCCCTTGGGTAACTTGCTGATATGTGAAGCGTGCTTCAGTTCATAC

PARP1 Mutant

TGATATGTGAAGCGTGCTTCAGTTCATAC

BRCA1 Wild Type

ACTCCAAACCTGTGTCAAGCTGAAAAGCACAAATGATTTTCAATAGCTCTTCAACAAGTTGACTAAATCTCGTAC
TTTCTTGTAGGCTC

BRCA1 Mutant

CTGTGTCAAGCTGAAAAGCACAAATGATTTTCAATAGCTCTTCAACAAGTTGACTAAATCTCGTACTTTCTTGTA
GGCTC

ARID2 Wild Type

AACGGTCTTTCCAAATCATACAGTGAAGAGAGTGGAGGATTCCAGTAGCAATGGGCAGGCACATATTCATGTGG
TAGGAGTAAAACGGAGGGCTATACCACTTCCCATTCAGATGTACTATCAGCAGCAACCAGTTTCTACTTCTGTTG
TTCGTGTTGATTCTGTTCCTGATGTATCTCCTGCTCCTTCACCTGCAG

ARID2 Mutant

AACGGTCTTTCCAAATCATACAGTGAAGAGAGTGGAGGATTCCAGTAGCAATGGGCAGGCACATATTCATGAG

PTEN Wild Type

TTGCACAATATCCTTTTGAAGACCATAACCCACCACAGCTAGAACTTATCAAACCCTTTTGTGAAGATCTTGACC
AATGGCTAAGTGAAGATGACAATCATGTTGCAGCAATTCACTGTAAAGCTGGAAAGGGACGAACTGGTGTAATG
ATATGTGCATATTTATTACATCGGGGCAAATTTTTAAAGGCACAAGAGGCCCTAGATTTCTATGGGGAAGTAAGG
ACCAGAGACAAAAAG

PTEN Mutant

TTGCACAATATCCTTTTGAAGACCATAACCCACCACAGCTAGAACTTATCAAACCCTTTTGTGAAGATCTTGACC
AATGGCTAAGTGAAGATGACAATCATGTTGCAGCAATTCACTGTAAAGCTGGAAAGGGACGAACTGGTGTAATG
ATATGTGCATATTTATTACATCGGGGCAAATTTTTAAAGGCACAAGAGGCCCTAGATTTCTATGGGGAA

CDH1 Wild Type

GACTTTGACTTGAGCCAGCTGCACAGGGGCCTGGACGCTCGGCCTGAAGTGACTCGTAACGACGTTGCACCA
ACCCTCATGAGTGTCCCCCGGTATCTTCCCCGCCCTGCCAATCCCGATGAAATTGGAAATTTTATTGATGAA

CDH1 Mutant

GACTTTGACTTGAGCCAGCTGCACAGGGGCCTGGACGCTCGGCCTGAAGTGACTCGTAACGACGTTGCACCA
ACCCTCATGAGTGTCCCCCG

TSC2 Wild Type

AGGGGTTTTCTGGTGCGTCCTGGTCCACCATGGCCAAACCAACAAGCAAAGATTCAGGCTTGAAGGAGAAGT
TTAAGATTCTGTTGGGACTGGGAACACCGAGGCCAAATCCCAGGTCTGCAGAGGGTAAACAGACGGAGTTTAT
CATCACCGCGGAAATACTGAGA

TSC2 Mutant

AGGGGTTTTCTGGTGCGTCCTGGTCCACCATGGCCAAACCAACAAGCAAAGATTCAGGCTTGAAGGAGAAGT
TTAAGATTCTGTTGGGACTGGGAACACCGAGGCCAAATCCCAG

Supplemental Table 7: Predicted alternative and wild-type RT-PCR splice products from mini-gene
splicing assay. Related to Experimental Procedures.
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Figure S1. BAP1 gene and protein expression. Related to Figure 5. Violin plot of RSEM and
RPPA data for control samples (grey) and novel splice creating mutant samples (red).
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Figure S2. Comparison of neoantigen predictions betweeen NetMHC4 and NetMHCPan. Related to Figure 6. The predicted number of neoantigens from NetMHC4 and NetMHCpan-3.0

3

1

WT

V596E

WT

V596E

Replicate 2

WT

V596E

Replicate 3

ARID2 - 124 bp deletion - Spliced In

2

Replicate 1
PCAS2.1 Ladder

2

1

F.

E.

BCOR Mutant
Sequence

BCOR WT
Sequence

1

WT

2

R1375W

Replicate 1

BCOR
R1375W

WT

R1375W

Replicate 3

BCOR- 52 bp deletion

WT

Replicate 2

I.

2

1

H.

BRCA1 Mutant
Sequence

BRCA1 WT
Sequence

G.

1

BRCA1

Replicate 2

Replicate 3
WT c.301+2

BRCA1 - 9 bp deletion for splice site mutant

2

WT c.301+2 WT c.301+2

Replicate 1

Nontransfected

pCAS2.1

Figure S3. ARID2, BCOR, BRCA1 Mini-Gene results. Related to Figure 5. (A,D,G) DNA chromatograms verifying ARID2, BCOR,
and BRCA1 wildtype and mutant sequencing results, respectively. Mutation position is highlighted. (B,E,H) Reverse transcriptase PCR
(RT-PCR) with wild type and mutant plasmids, results in triplicate. Numbered bands are sequenced for confirmation. (C,F,I) DNA chromatograms of RT-PCR bands sequenced. Highlighted sequence indicates boundary of pCAS2.1 plasmid.
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Figure S4. PTEN, PARP1, KMT2A Mini-Gene results. Related to Figure 5. (A,D,G) DNA chromatograms verifying PTEN, PARP1,
and KMT2A wildtype and mutant sequencing results, respectively. Mutation position is highlighted. (B,E,H) Reverse transcriptase PCR
(RT-PCR) with wild type and mutant plasmids, results in triplicate. Numbered bands are sequenced for confirmation. (C,F,I) DNA chromatograms of RT-PCR bands sequenced. Highlighted sequence indicates boundary of pCAS2.1 plasmid.
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Figure S5. RAD51C, TP53, TSC2 Mini-Gene results. Related to Figure 5. (A,D,G) DNA chromatograms verifying RAD51C, TP53,
and TSC2 wildtype and mutant sequencing results, respectively. Mutation position is highlighted. (B,E,H) Reverse transcriptase PCR
(RT-PCR) with wild type and mutant plasmids, results in triplicate. Numbered bands are sequenced for confirmation. (C,F,I) DNA chromatograms of RT-PCR bands sequenced. Highlighted sequence indicates boundary of pCAS2.1 plasmid.
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Figure S6. BAP1 and CDH1 Mini-Gene results. Related to Figure 5. (A,D) DNA chromatograms verifying BAP1 and CDH1 wildtype
and mutant sequencing results, respectively. Mutation position is highlighted. (B,E) Reverse transcriptase PCR (RT-PCR) with wild type
and mutant plasmids, results in triplicate. Numbered bands are sequenced for confirmation. (C,F) DNA chromatograms of RT-PCR
bands sequenced. Highlighted sequence indicates boundary of pCAS2.1 plasmid.
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